Molecular Oncology
Volume 1, Issue 3 , Pages 321-349 , December 2007

Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: Relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease

  • Julio E. Celis

      Affiliations

    • Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100, Copenhagen, Denmark
    • Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
    • Corresponding Author InformationCorresponding author at: Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100, Copenhagen, Denmark. Tel.: +45 3525 7363; fax: +45 3525 7375.
    • ,
  • Irina Gromova

      Affiliations

    • Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100, Copenhagen, Denmark
    • Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
    • ,
  • Teresa Cabezón

      Affiliations

    • Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100, Copenhagen, Denmark
    • Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
    • ,
  • Pavel Gromov

      Affiliations

    • Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100, Copenhagen, Denmark
    • Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
    • ,
  • Tao Shen

      Affiliations

    • Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100, Copenhagen, Denmark
    • Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
    • Present address: Institute of Basic Medicine, The First People's Hospital of Yunnan Province, Yunnan, PR China.
    • ,
  • Vera Timmermans-Wielenga

      Affiliations

    • Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100, Copenhagen, Denmark
    • Department of Pathology, The Centre of Diagnostic Investigations, Rigshospitalet, Copenhagen, Denmark
    • ,
  • Fritz Rank

      Affiliations

    • Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100, Copenhagen, Denmark
    • Department of Pathology, The Centre of Diagnostic Investigations, Rigshospitalet, Copenhagen, Denmark
    • ,
  • José M.A. Moreira

      Affiliations

    • Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100, Copenhagen, Denmark
    • Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark

Received 24 August 2007 ,Revised 12 September 2007 ,Accepted 13 September 2007.

References 

  1. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26:1324–1337(Review)
  2. Adriance MC, Inman JL, Petersen OW, Bissell MJ. Myoepithelial cells: good fences make good neighbors. Breast Cancer Res. 2005;7:190–197
  3. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2003;100:3983–3988
  4. Arai K, Teratani T, Kuruto-Niwa R, Yamada T, Nozawa R. S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation. Eur. J. Cancer. 2004;40:1179–1187
  5. Asselin-Labat ML, Shackleton M, Stingl J, Vaillant F, Forrest NC, Eaves CJ, et al. Steroid hormone receptor status of mouse mammary stem cells. J. Natl. Cancer Inst. 2006;98:1011–1014
  6. Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC, et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat. Cell Biol. 2007;9:201–209
  7. Bartek J, Taylor-Papadimitriou J, Miller N, Millis R. Patterns of expression of keratin 19 as detected with monoclonal antibodies in human breast tissues and tumours. Int. J. Cancer. 1985;36:299–306
  8. Bartek J, Bartkova J, Taylor-Papadimitriou J. Keratin 19 expression in the adult and developing human mammary gland. Histochem. J. 1990;22:537–544
  9. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, Adelaide J, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res. 2006;66:4636–4644
  10. Berx G, Cleton-Jansen AM, Strumane K, de Leeuw WJ, Nollet F, van Roy F, et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene. 1996;13:1919–1925
  11. Binder C, Marx D, Overhoff R, Binder L, Schauer A, Hiddemann W. Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables. Ann. Oncol. 1995;6:1005–1010
  12. Birrell SN, Hall RE, Tilley WD. Role of the androgen receptor in human breast cancer. J. Mammary Gland Biol. Neoplasia. 1998;3:95–103(Review)
  13. Blanpain C, Horsley V, Fuchs E. Epithelial stem cells: turning over new leaves. Cell. 2007;128:445–458(Review)
  14. Bogaerts J, Cardoso M, Buyse S, Braga S, Loi JA, Harrison J, et al. TRANSBIG consortium. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat. Clin. Pract. Oncol. 2006;3:540–551(Review)
  15. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, et al. TRANSBIG Consortium. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl. Cancer Inst. 2006;98:1183–1192
  16. Carlsson H, Yhr M, Petersson S, Collins N, Polyak K, Enerback C. Psoriasin (S100A7) and calgranulin-B (S100A9) induction is dependent on reactive oxygen species and is downregulated by Bcl-2 and antioxidants. Cancer Biol. Ther. 2005;4:998–1005
  17. Celis JE, Gromov P, Cabezon T, Moreira JM, Ambartsumian N, Sandelin K, et al. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol. Cell. Proteomics. 2004;3:327–344
  18. Celis JE, Moreira JM, Cabezon T, Gromov P, Friis E, Rank F, et al. Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Mol. Cell. Proteomics. 2005;4:492–522
  19. Celis JE, Trentemølle S, Gromov P. Gel-based proteomics: high-resolution two-dimensional gel electrophoresis of proteins. Isoelectric focusing (IEF) and nonequilibrium pH gradient electrophoresis (NEPHGE). In:  Celis JE,  Carter N,  Hunter T,  Shotton D,  Simons K,  Small JV editor. Cell Biology. A Laboratory Handbook. 4:San Diego, CA: Elsevier; 2005;p. 165–177
  20. Celis JE, Gromova I, Gromov P, Moreira JM, Cabezon T, Friis E, et al. Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia. FEBS Lett. 2006;580:2935–2944(Review)
  21. Celis JE, Gromov P, Moreira JM, Cabezon T, Friis E, Vejborg IM, et al. Apocrine cysts of the breast: biomarkers, origin, enlargement, and relation with cancer phenotype. Mol. Cell. Proteomics. 2006;5:462–483
  22. Celis JE, Moreira JMA, Gromov P. Determination of antibody specificity by Western blotting. In:  Celis JE,  Carter N,  Hunter T,  Simons K,  Small JV,  Shotton D editor. third ed.. A Cell Biology. Laboratory Handbook. 4:San Diego: Academic Press; 2006;p. 527–532
  23. Celis JE, Moreira JM, Gromova I, Cabezon T, Gromov P, Shen T, et al. Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia. Mol. Onc. 2007;1:97–119
  24. Ciocca V, Bombonati A, Gatalica Z, Di Pasquale M, Milos A, Ruiz-Orrico A, et al. Cytokeratin profiles of male breast cancers. Histopathology. 2006;49:365–370
  25. Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, et al. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J. Clin. Oncol. 1998;16:470–479
  26. Clarke RB. Isolation and characterization of human mammary stem cells. Cell Prolif. 2005;38:375–386(Review)
  27. Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell. 2006;124:1111–1115
  28. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946–10951
  29. Dabbs DJ, Carter G, Fudge M, Peng Y, Swalsky P, Finkelstein S. Molecular alterations in columnar cell lesions of the breast. Mod. Pathol. 2006;19:344–349
  30. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Ann. Rev. Med. 2007;58:267–284
  31. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer. 2005;5:275–284
  32. Deugnier MA, Teuliere J, Faraldo MM, Thiery JP, Glukhova MA. The importance of being a myoepithelial cell. Breast Cancer Res. 2002;4:224–230
  33. Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS. Stem cells in normal breast development and breast cancer. Cell Prolif. 2003;1:59–72
  34. Dontu G, Liu S, Wicha MS. Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev. 2005;1:207–213
  35. Eckfeldt CE, Mendenhall EM, Verfaillie CM. The molecular repertoire of the ‘almighty’ stem cell. Nat. Rev. Mol. Cell Biol. 2005;6:726–737
  36. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403–410
  37. Emberley ED, Murphy LC, Watson PH. S100A7 and the progression of breast cancer. Breast Cancer Res. 2004;6:153–159
  38. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005;24:4660–4671
  39. Fata JE, Werb Z, Bissell MJ. Regulation of mammary gland branching morphogenesis by the extracellular matrix and its remodeling enzymes. Breast Cancer Res. 2004;6:1–11
  40. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 2007;18:581–592
  41. Figueira EC, Di Girolamo N, Coroneo MT, Wakefield D. The phenotype of limbal epithelial stem cells. Invest. Ophthalmol. Vis. Sci. 2007;48:144–156
  42. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64:7011–7021
  43. Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics. 2006;7:278
  44. Going JJ, Moffat DF. Escaping from Flatland: clinical and biological aspects of human mammary duct anatomy in three dimensions. J. Pathol. 2004;203:538–544
  45. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meetings highlights: updated international expert consensus on the primary therapy of early breast cancer. J. Clin. Oncol. 2003;21:1–8
  46. Gromova I, Celis JE. Protein detection in gels by silver staining: a procedure compatible with mass-spectrometry. In:  Celis JE,  Carter N,  Hunter T,  Shotton D,  Simons K,  Small JV editor. Cell Biology. A Laboratory Handbook. vol. 4:San Diego: Academic Press; 2006;p. 219–223
  47. Gudjonsson T, Adriance MC, Sternlicht MD, Petersen OW, Bissell MJ. Myoepithelial cells: their origin and function in breast morphogenesis and neoplasia. J. Mammary Gland Biol. Neoplasia. 2005;10:261–272
  48. Herceg Z, Hainaut P. Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. Mol. Oncol. 2007;1:26–41
  49. Hesse M, Zimek A, Weber K, Magin TM. Comprehensive analysis of keratin gene clusters in humans and rodents. Eur. J. Cell Biol. 2004;83:19–26
  50. Hussain SA, Palmer DH, Spooner D, Rea DW. Molecularly targeted therapeutics for breast cancer. BioDrugs. 2007;21:215–224
  51. Jih DM, Lyle S, Elenitsas R, Elder DE, Cotsarelis G. Cytokeratin 15 expression in trichoepitheliomas and a subset of basal cell carcinomas suggests they originate from hair follicle stem cells. J. Cutan. Pathol. 1999;26:113–118
  52. Jones C, Damiani S, Wells D, Chaggar R, Lakhani SR, Eusebi V. Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast. Am. J. Pathol. 2001;158:207–214
  53. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 2006;24:2137–2150
  54. Klijn JG, Berns EM, Foekens JA. Prognostic factors and response to therapy in breast cancer. Cancer Surv. 1993;18:165–198
  55. Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell. 2006;127:1041–1055
  56. Krop I, Marz A, Carlsson H, Li X, Bloushtain-Qimron N, Hu M, et al. A putative role for psoriasin in breast tumor progression. Cancer Res. 2005;65:11326–11334
  57. Lacroix M. Significance, detection and markers of disseminated breast cancer cells. Endocr. Relat. Cancer. 2006;13:1033–1067
  58. Lerwill MF. Current practical applications of diagnostic immunohistochemistry in breast pathology. Am. J. Surg. Pathol. 2004;28:1076–1091
  59. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod. Pathol. 2006;19:264–271
  60. Lobo, N.A., Shimono Y, Qian D, Clarke, M.F., 2007. The biology of cancer stem cells. Annu. Rev. Cell. Dev. Biol., in press. doi:10.1146/annurev.cellbio.22.010305.104154.
  61. Lynch MD, Cariati M, Purushotham AD. Breast cancer, stem cells and prospects for therapy. Breast Cancer Res. 2006;8:211
  62. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore!. Curr. Opin. Cell. Biol. 2001;13:534–540
  63. Mies C, Rosen PP. Juvenile fibroadenoma with atypical epithelial hyperplasia. Am. J. Surg. Pathol. 1987;11:184–190
  64. Moll R, Moll I. Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Subcell. Biochem. 1998;31:205–262
  65. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31:11–24
  66. Moreira JM, Ohlsson G, Rank F, Celis JE. Down-regulation of the tumor suppressor protein 14-3-3sigma is a sporadic event in cancer of the breast. Mol. Cell. Proteomics. 2005;4:555–569
  67. Moriya T, Kasajima A, Ishida K, Kariya Y, Akahira J, Endoh M, et al. New trends of immunohistochemistry for making differential diagnosis of breast lesions. Med. Mol. Morphol. 2006;39:8–13
  68. Nemoto T, Natarajan N, Bedwani R, Vana J, Murphy GP. Breast cancer in the medial half. Results of 1978 National Survey of the American College of Surgeons. Cancer. 1983;51:1333–1338
  69. Nevins JR, Huang ES, Dressman H, Pittman J, Huang AT, West M. Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction. Hum. Mol. Genet. 2003;12:R153–R157
  70. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J. Biol. Chem. 1975;250:4007–4021
  71. Ohuchi N, Abe R, Takahashi T, Tezuka F. Origin and extension of intraductal papillomas of the breast: a three-dimensional reconstruction study. Breast Cancer Res. Treat. 1984;4:117–128
  72. Ohyama M, Terunuma A, Tock CL, Radonovich MF, Pise-Masison CA, Hopping SB, et al. Characterization and isolation of stem cell-enriched human hair follicle bulge cells. J. Clin. Invest. 2006;116:249–260
  73. Ostergaard M, Wolf H, Orntoft TF, Celis JE. Psoriasin (S100A7): a putative urinary marker for the follow-up of patients with bladder squamous cell carcinomas. Electrophoresis. 1999;20:349–354
  74. Page DL. A typical hyperplasia, narrowly and broadly defined. Hum Pathol. 1991;22(7):631–632
  75. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002, CA Cancer. J. Clin. 2005;55:74–108
  76. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene. 2006;25:1696–1708
  77. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752
  78. Pinder SE, Reis-Filho JS. Non Operative Breast Pathology: columnar cell lesions. J. Clin. Pathol. 2006;1–12
  79. Polyak K, Hahn WC. Roots and stems: stem cells in cancer. Nat. Med. 2006;12:296–300
  80. Polyak K, Hu M. Do myoepithelial cells hold the key for breast tumor progression?. J. Mammary Gland Biol. Neoplasia. 2005;10:231–247
  81. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005;65:5506–5511
  82. Rack B, Janni W, Gerber B, Strobl B, Schindlbeck C, Klanner E, et al. Patients with recurrent breast cancer: does the primary axillary lymph node status predict more aggressive tumor progression?. Breast Cancer Res. Treat. 2003;82:83–92
  83. Rohan TE, Li SQ, Hartwick R, Kandel RA. p53 Alterations and protein accumulation in benign breast tissue and breast cancer risk: a cohort study. Cancer Epidemiol. Biomarkers Prev. 2006;15:1316–1323
  84. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 2000;24:227–235
  85. Russo J, Russo IH. Development of the human breast. Maturitas. 2004;49:2–15
  86. Russo J, Moral R, Balogh GA, Mailo D, Russo IH. The protective role of pregnancy in breast cancer. Breast Cancer Res. 2005;7:131–142
  87. Sagar J, Chaib B, Sales K, Winslet M, Seifalian A. Role of stem cells in cancer therapy and cancer stem cells: a review. Cancer Cell Int. 2007;7:9
  88. Schweizer J, Bowden PE, Coulombe PA, Langbein L, Lane EB, Magin TM, et al. New consensus nomenclature for mammalian keratins. J. Cell Biol. 2006;174:169–174
  89. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 1996;68:850–858
  90. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007;11:259–273
  91. Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet. 1995;345:1154–1157
  92. Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P, et al. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J. Clin. Oncol. 1996;14:1604–1610
  93. Simpson PT, Gale T, Reis-Filho JS, Jones C, Parry S, Sloane JP, et al. Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. Am. J. Surg. Pathol. 2005;29:734–746
  94. Skliris GP, Lewis A, Emberley E, Peng B, Weebadda WK, Kemp A, et al. Estrogen receptor-beta regulates psoriasin (S100A7) in human breast cancer. Breast Cancer Res. Treat. 2007;104:75–85
  95. Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur. J. Cancer. 2004;40:2275–2667
  96. Sorlie T. Molecular classification of breast tumors: toward improved diagnostics and treatments. Methods Mol. Biol. 2007;360:91–114
  97. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 2001;98:10869–10874
  98. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U.S.A. 2003;100:8418–8423
  99. Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 2006;7:127–142
  100. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?. Nat. Rev. Cancer. 2007;7:545–553
  101. Sugai M, Murata K, Kimura N, Munakata H, Hada R, Kamata Y. Adenoma of the nipple in an adolescent. Breast Cancer. 2002;9:254–256
  102. Sutherland KD, Lindeman GJ, Visvader JE. Knocking off SOCS genes in the mammary gland. Cell Cycle. 2007;6:799–803
  103. Tavassoli FA, Norris HJ. Intraductal apocrine carcinoma: a clinicopathologic study of 37 cases. Mod. Pathol. 1994;7:813–818
  104. The World Health Organization . WHO classification of tumors. Tumors of the Breast and Female Genital Organs. In:  Tavassoli F,  Devilee P editor. Lyon, France: IARC Press; 2003;
  105. Tsai YC, Lu Y, Nichols PW, Zlotnikov G, Jones PA, Smith HS. Contiguous patches of normal human mammary epithelium derived from a single stem cell: implications for breast carcinogenesis. Cancer Res. 1996;56:402–404
  106. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984;226:1097–1099
  107. Tysnes BB, Bjerkvig R. Cancer initiation and progression: Involvement of stem cells and the microenvironment. Biochim. Biophys. Acta. 2007;1775:283–297
  108. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002;347:1999–2009
  109. van Diest PJ, van der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J. Clin. Pathol. 2004;57:675–681
  110. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536
  111. Vartanian RK, Weidner N. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am. J. Pathol. 1994;144:1188–1194
  112. Villadsen R, Fridriksdottir AJ, Ronnov-Jessen L, Gudjonsson T, Rank F, LaBarge MA, et al. Evidence for a stem cell hierarchy in the adult human breast. J. Cell Biol. 2007;177:87–101
  113. Vincent-Salomon A, Gruel N, Lucchesi C, MacGrogan G, Dendale R, Sigal-Zafrani B, et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res. 2007;9:R24
  114. Webb A, Li A, Kaur P. Location and phenotype of human adult keratinocyte stem cells of the skin. Differentiation. 2004;72:387–395
  115. Weissman I. Stem cell research: paths to cancer therapies and regenerative medicine. JAMA. 2005;294:1359–1366
  116. Weissman IL. Normal and neoplastic stem cells. Novartis Found. Symp. 2005;265:37–92
  117. Wellings SR, Alpers CE. Apocrine cystic metaplasia: subgross pathology and prevalence in cancer-associated versus random autopsy breasts. Hum. Pathol. 1987;18:381–386
  118. Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J. Natl. Cancer Inst. 1975;55:231–273
  119. Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol. Biol. Cell. 2002;13:1977–2000
  120. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea—a paradigm shift. Cancer Res. 2006;66:1883–1890
  121. Wiseman BS, Werb Z. Stromal effects on mammary gland development and breast cancer. Science. 2002;296:1046–1049
  122. Zucchi I, Sanzone S, Astigiano S, Pelucchi P, Scotti M, Valsecchi V, et al. The properties of a mammary gland cancer stem cell. Proc. Natl. Acad. Sci. U.S.A. 2007;104:10476–10481

PII: S1574-7891(07)00072-5

doi: 10.1016/j.molonc.2007.09.004

Molecular Oncology
Volume 1, Issue 3 , Pages 321-349 , December 2007

Article Tools

* Image Usage & Resolution